Bronchiectasis appears to share genetic signals with chronic obstructive pulmonary disease (COPD), asthma, and chronic bronchitis, and a cross-ancestry genetic analysis of more than 1.8 million people ...

Brensocatib hydrate (Brinsupri; Insmed Inc) launched commercially in Japan on October 19 for adults and children 12 years and ...

Bronchiectasis, a chronic inflammatory lung disease characterized by clinical cough, sputum production and recurrent respiratory infections, is entering the spotlight, with clinic ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Individuals with non-cystic fibrosis bronchiectasis may experience partial cystic fibrosis transmembrane conductance regulator dysfunction (CFTR-RD) that can be identified and treated with highly ...

This article explains the role and future prospects of dipeptidyl peptidase 1 (DPP1) inhibitors as treatments for ...

Updated clinical guidelines for adult bronchiectasis suggest long-term macrolide or brensocatib therapy to reduce frequent ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

Cindy has always been active. As a physical education teacher, and later an elementary school principal, she built her career ...

Imagine trying to live a normal life when you can’t stop coughing or you’re too breathless to walk. For many people living with bronchiectasis, that’s the reality they face every day. Recurring ...

Insmed Incorporated announced the commercial launch in Japan of BRINSUPRI Tablets 25 mg (brensocatib hydrate), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and ...